Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197154 | 0.79 | SIRT3 (0.36) | SMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL2184004 | 0.79 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1KMT2ANPC1MAPT | |
| SCHEMBL4886319 | 0.76 | MKNK1 (0.40) | ALDH1A1KMT2ANPC1MAPTHPGD | |
| SCHEMBL20097035 | 0.76 | FGFR1 (0.36) | SMN1; SMN2JAK2JAK3 | |
| SCHEMBL27582500 | 0.75 | LTA4H (0.35) | SMN1; SMN2JAK2JAK3ALDH1A1KMT2A | |
| SCHEMBL2182600 | 0.73 | HDAC6 (0.42) | SMN1; SMN2ALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL2183866 | 0.70 | HDAC1 (0.42) | SMN1; SMN2ALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL2180309 | 0.70 | KMT2A (0.46) | SMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL84793 | 0.69 | LTA4H (0.41) | JAK2JAK3ALDH1A1MAPT | |
| SCHEMBL1106468 | 0.68 | NFATC1 (0.45) | SMN1; SMN2JAK2JAK3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | FAAH, FAAH2, MGLL | SMN1; SMN2 4682/4885JAK2 3414/4885JAK3 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.